405170-93-6

Basic information

• Product Name: Benzenamine, 2-nitro-4-(2-thienyl)-
• CAS NO: 405170-93-6
• Molecular Formula: C10H8N2O2S
• Molecular Weight: 220.252
• Mol File: 405170-93-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzenamine, 2-nitro-4-(2-thienyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenamine, 2-nitro-4-(2-thienyl)-(405170-93-6)
• EPA Substance Registry System: Benzenamine, 2-nitro-4-(2-thienyl)-(405170-93-6)

Safety Data

• Hazardous Substances Data: 405170-93-6(Hazardous Substances Data)

Upstream product

• 875-51-4 4-Bromo-2-nitroaniline 
• 6165-68-0 thiophene boronic acid 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 

Downstream Products

• 849235-61-6 4-[(3,4-dimethoxy-phenylamino)-methyl]-N-(2-nitro-4-thiophen-2-yl-phenyl)-benzamide 
• 471239-63-1 4-(thiophen-2-yl)benzene-1,2-diamine 
• 1352637-82-1 3,4,5-trimethoxy-N-(2-nitro-4-thiophen-2-yl-phenyl)benzamide 
• 1352638-02-8 3,4-dihydroxy-5-methoxy-N-(2-nitro-4-(thiophen-2-yl)phenyl)benzamide 

Relevant articles and documents

Potent galloyl-based selective modulators targeting multidrug resistance associated protein 1 and P-glycoprotein

The multifactorial nature of chemotherapy failure in controlling cancer is often associated with the occurrence of multidrug resistance (MDR), a phenomenon likely related to the increased expression of members of the ATP binding cassette (ABC) transporter superfamily. In this respect, the most extensively characterized MDR transporters include ABCB1 (also known as MDR1 or P-glycoprotein) and ABCC1 (also known as MRP1) whose inhibition remains a priority to circumvent drug resistance. Herein, we report how the simple galloyl benzamide scaffold can be easily and properly decorated for the preparation of either MRP1 or P-gp highly selective inhibitors. In particular, some gallamides and pyrogallol-1-monomethyl ethers showed remarkable affinity and selectivity toward MRP1. On the other hand, trimethyl ether galloyl anilides, with few exceptions, exhibited moderate to very high and selective P-gp inhibition.

Combination therapy with CHK1 inhibitors

Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

INHIBITORS OF HISTONE DEACETYLASE

The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.